Angiotensin-converting enzyme (ACE) has a critical role in cardiovascular function by cleaving the carboxy terminal His-Leu dipeptide from angiotensin I to produce a potent vasopressor octapeptide, angiotensin II. Inhibitors of ACE are a first line of therapy for hypertension, heart failure, myocardial infarction and diabetic nephropathy. Notably, these inhibitors were developed without knowledge of the structure of human ACE, but were instead designed on the basis of an assumed mechanistic homology with carboxypeptidase A 1 . Here we present the X-ray structure of human testicular ACE and its complex with one of the most widely used inhibitors, lisinopril (N 2 -[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; also known as Prinivil or Zestril), at 2.0 Å resolution. Analysis of the three-dimensional structure of ACE shows that it bears little similarity to that of carboxypeptidase A, but instead resembles neurolysin 2 and Pyrococcus furiosus carboxypeptidase 3 -zinc metallopeptidases with no detectable sequence similarity to ACE. The structure provides an opportunity to design domainselective ACE inhibitors that may exhibit new pharmacological profiles.
Angiotensin-converting enzyme (also known as peptidyl dipeptidase A, EC 3.4.15.1 or ACE) is a type-I membrane-anchored dipeptidyl carboxypeptidase that is essential for blood pressure regulation and electrolyte homeostasis through the renin-angiotensin-aldosterone system. There are two isoforms of ACE that are transcribed from the same gene in a tissue-specific manner. In somatic tissues it exists as a glycoprotein composed of a single, large polypeptide chain of 1,277 amino acids, whereas in sperm cells it is a lower-molecular-mass glycoform of 701 amino acids. The somatic form consists of two homologous domains (N and C domain), each of which contains an active site with a conserved HEXXH zincbinding motif 4 , where the two histidines are zinc ligands, with a glutamate 24 residues downstream forming the third ligand 5 . The two domains differ in their substrate specificities, inhibitor and chloride activation profiles, and physiological functions 6 . There are two N-domain-specific substrates: the peptide N-acetyl-serylaspartyl-lysyl-proline, which regulates haematopoietic stem cell differentiation and proliferation; and the bradykinin-potentiating peptide angiotensin-(1-7) 7 . On the other hand, the active sites of both domains catalyse the hydrolysis of angiotensin I and the vasodilator bradykinin with similar efficiency. However, inhibition of the N domain with a phosphinic peptide RXP407 has no effect on blood pressure regulation 7 , and expression in transgenic mice of the N domain alone produces a phenotype similar to that seen in complete ACE knockout mice 8 . Thus, the C domain seems to be necessary and sufficient for controlling blood pressure and cardiovascular function, suggesting that the C domain is the dominant angiotensin-converting site.
Testis ACE is identical to the C-terminal half of somatic ACE, except for a unique 36-residue sequence constituting its amino terminus 9 . We used a truncated version, tACED36NJ (a mutant with full enzymatic activity that is truncated at Ser 625 and that lacks the O-glycan-rich, N-terminal 36 residues and hydrophobic transmembrane domain), for structure determination. The carbohydrates were modified to minimize oligosaccharide-based heterogeneity 10 . We refer to this as tACE.
The structure of tACE (residues 37-625) adopts an overall ellipsoid shape (dimensions approximately 72 £ 57 £ 48 Å ) with a central groove that extends for about 30 Å into the molecule and divides the protein into two 'subdomains' (labelled I and II in Fig. 1a) . The boundaries of the groove are provided by helices a13, a14, a15, a17 and strand b4. The structure of the tACE-lisinopril complex was used to locate the active site of the molecule. On top of the molecule there is an N-terminal 'lid' formed by helices a1, a2 and a3 (all three containing several charged residues), which seems to restrict the access of large polypeptides to the active-site cleft and thereby accounts for the enzyme's inability to hydrolyse large, folded substrates (Fig. 1b) . The structure of tACE is predominantly helical with 27 helices (almost equally distributed in both subdomains), 20 a-helices and seven 3 10 -helices (Fig. 1a, c) . The only b-structure, accounting for 4% of all residues, occurs as six relatively short strands, two of which are located near the active site (Fig. 1a) . The long central helix a15 packs diagonally across the two kinked helices a6 and a8 (both of them contain a proline residue).
Residues Asp 40 (a1) and Gly 615 (five residues downstream of a20) define the N and C termini of the ectodomain, respectively, and this is in agreement with previous tACE mutagenesis and cleavage-secretion studies 11 . Residues Ser 435 to Gly 438 are disordered in the structure. A total of 504 water molecules were identified in the native structure. The active-site pocket is occupied by several ordered water molecules. All six glycosylation sites (g1-6, Fig. 1c ) are located on the surface of the tACE molecule. Weak electron density was observed for N-linked carbohydrates in all of the glycosylation sites and modelled with an N-acetylglucosamine moiety.
Zinc is an important catalytic component of ACE 6, 12 . One highly ordered zinc ion (B-factor ¼ 16.3 Å 2 in tACE-native) is bound at the active site. Helix a13 contains the HEXXH zinc-binding motif, with its two zinc-coordinating histidines (His 383 and His 387). Additional coordination is provided by Glu 411 on helix a14 and an acetate ion (from the crystallization medium). The role of a zinc ion in ACE catalysis was thought to be analogous to that in thermolysin 4 , and our structural data confirm that the zinc-binding sites in both proteins are indeed very similar (root mean square (r.m.s.) deviation of 0.52 Å (all atoms) for residues that are zinc ligands in both proteins), except for the acetate ion that is replaced by a water molecule in the coordination sphere in thermolysin.
Substrate hydrolysis by ACE is activated by chloride ion in a substrate-dependent manner 13, 14 . The C-domain active site, but not the N domain, in ACE is strongly activated by chloride ion 15 . The structure of tACE revealed the location of two buried chloride ions separated by 20.3 Å (Fig. 1a) . The first (Cl1, 20.7 Å away from the zinc ion) is bound to four ligands-Arg 489 (NH1), Arg 186 (NE), Trp 485 (NE1) and water-and is surrounded by a hydrophobic shell of four tryptophans. The second (Cl2, 10.4 Å away from the zinc ion) is bound to Arg 522 (NE, 3.1 Å ), in agreement with a previous report indicating that Arg 1098 (the analogous Arg residue in the C domain of somatic ACE) is critical for the chloride dependence of ACE activity 16 . Tyr 224 and a water molecule are the other two Cl2 ligands. Thus, binding of each chloride in tACE involves ligands from both subdomains (Fig. 1c) . It has been proposed that the chloride ion might interact with the substrate as well as the enzyme 16 . However, the location of both buried chloride ions outside the active site makes such an interaction unlikely. The molecular mechanism of chloride activation is not readily apparent from the structure; however, the primary ligand for Cl2, Arg 522, lies on the same helix (a17) as two residues (Tyr 520 and Tyr 523) that interact with lisinopril and, presumably, substrate as well (Figs 1c and 2a) .
ACE belongs to the M2 family of zinc-binding metallopeptidases, within the MA clan. Apart from the HEXXH metal-coordinating motif, there is little sequence homology between ACE and other members of the MA clan. Structural comparison of tACE with other protein structures using the DALI server 17 revealed significant homology with neurolysin 2 , a protein involved in neurotensin metabolism (Fig. 3a, b) , and a carboxypeptidase from the hyperthermophilic archaeon P. furiosus 3 . Neurolysin is a member of the M3 family of oligopeptidases (a member of the MA clan), and P. furiosus carboxypeptidase is a member of the M32 family of carboxypeptidases. Similar to ACE, both belong to the family of metallopeptidases bearing the HEXXH active-site motif 18 and consist of an abundance of a-helices with very little b-structure. The two proteins exhibit little amino-acid sequence similarity with tACE, yet when the two structures are optimally superimposed, there is a noticeable match with an r.m.s. deviation of 3.4 Å for 361 Ca atoms and 3.11 Å for 399 Ca atoms against neurolysin and P. furiosus carboxypeptidase, respectively. The core structures for Figure 1 Overview of tACE structure. a, Stereo view of the ribbon representation of the molecule looking down on the active site. The molecule can be divided into two portions, as subdomains I and II (cyan and pink, respectively). The active-site zinc ion and the lisinopril molecule are shown in green and yellow, respectively. The two chloride ions are shown as red spheres. b, Molecular surface representation (negative and positive potentials in red and blue, respectively) showing the active-site groove. The view is at 908 (towards the observer) to a. For clarity, the molecular surface has been sliced. The buried lisinopril molecule is shown in yellow. Helices a1, a2 and a3 forming the lid are shown. c, The structure-sequence relationship in tACE 10 . The secondary structure elements (subdomain I in cyan; subdomain II in pink) follow the same colour code as in a. a, a-helices; b, b-strands; H, 3 10 helices. The important residues that are involved in binding are indicated as follows: zinc ligands, green boxes; chloride-binding residues, orange (Cl1) and red (Cl2) boxes; lisinopril-binding residues, yellow boxes; and glycosylation sites, black boxes. these three proteins are similar, with significant differences in loops on the outer surface. The marked similarity also extends to the active-site region in neurolysin and P. furiosus carboxypeptidase, which consists of a deep narrow channel (about 20% larger accessible surface area than in tACE) that divides the molecule into two halves, and which only allows access to small peptide substrates. Notably, ACE also acts on neurotensin among its wide range of substrates 19 . Structural comparison of tACE with thermolysin (M4 family) revealed that there was significant, but far less marked, structural similarity between them (r.m.s. deviation of 3.2 Å for 170 Ca atoms).
The structure of tACE bound to the potent inhibitor lisinopril 6, 20, 21 ðK i ¼ 2:7 £ 10 210 MÞ shows that the inhibitor binds in a highly ordered (overall B-factor of 15.26 Å 2 ), extended conformation, with the phenyl group stretching towards the lid (Fig. 1a,  b) and the lysine side chain parallel to the a13 helix containing the HEXXH motif (Fig. 2a) . The lisinopril molecule is buried about 10 Å inside the groove (as viewed in Fig. 1a ), in agreement with the previous studies on biotinylated derivatives of lisinopril with ACE 22 . No significant rearrangement of active-site residues was observed on complex formation and the chloride ions are bound as in the native structure. The carboxyalkyl carboxylate of lisinopril is well positioned to bind to the active-site zinc atom 20, 21 , and provides one coordinating ligand (provided by an acetate ion in the native structure). The other three ligands (two histidines and a glutamic acid) are the same in both structures. The second oxygen atom of this carboxylate is 2.6 Å away from the zinc atom and makes an H-bond interaction with Glu 384 (OE2 atom, which appears to be protonated, as the complex was crystallized at about pH 4.7) of the HEXXH motif (Fig. 2a, b) . The S 1 phenylpropyl group makes van der Waals interactions with Val 518, and the lysyl amine forms a weak H-bond with Glu 162 (OE2 atom, 3.4 Å ) at the S 1 0 subsite of tACE. Surprisingly, the C-terminal carboxylate, which was thought to interact with a positively charged arginine residue (based on chemical modification experiments 23 ), instead binds to a lysine (Lys 511) as well as to Tyr 520.
We have presented here a three-dimensional structure of tACE and the tACE-lisinopril complex. Our study provides a detailed picture of the active site, which could be used for the development of new, highly selective ACE inhibitors targeted to the C domain by structure-based, rational drug design. This approach should produce a new generation of ACE inhibitors with the potential for greater efficacy, fewer side effects and new treatment indications (for example, polycythaemia). Furthermore, the similarity of tACE with neurolysin and P. furiosus carboxypeptidase has shown a surprising structural conservation between these metallopeptidases. A
Methods

Purification, crystallization and data collection
Details of the production of recombinant tACE (tACED36NJ) and growth of crystals (by vapour diffusion) will be reported elsewhere (our own unpublished results). Structure determination and refinement
The crystal structure of the ACE-lisinopril complex was solved using MAD and Multiple Isomorphous Replacement with Anomalous Scattering (MIRAS) procedures. The position of the zinc atom was identified using anomalous difference Patterson maps calculated using diffraction data at peak wavelength. The MAD phases that we obtained were not very strong, and therefore additional phase information was obtained using MIRAS procedures with platinum (K 2 PtCl 4 ), palladium (K 2 PdCl 4 ) and osmium (OsCl 3 ) Figure 3 Comparison of tACE (a) and neurolysin (b) folds. The same view as in Fig. 1a is retained. letters to nature heavy-atom derivatives. The zinc site was used to obtain the starting phases for each derivative. Double difference Fourier maps calculated using the CCP4 program 25 gave the first major heavy-atom site, and the phases from the combined zinc and heavy-atom sites were used to locate additional major/minor sites for each derivative. All heavy-atom sites and the zinc site were refined to 2.8 Å resolution using both MLPHARE 25 and SHARP 26 . The overall figure of merit from SHARP was 0.38 (at 2.8 Å ) and was improved to 0.89 (at 2.0 Å ) by iterative solvent flattening, phase combination, and phase extension with the program SOLOMON 27 . We carried out model building and refinement using the programs O and CNS 28 , respectively. During the final stages of refinement, water molecules, zinc ion, acetate ion and the inhibitor molecule were inserted in the respective structures. Both the native and inhibitor complex structures were refined at 2.0 Å (see Supplementary Information) with 94% of the residues in the maximum allowed region and none in the disallowed region of the Ramachandran map. The final structures of ACE and the ACE-lisinopril complex had an R free value of 22.08% and 21.88%, and a final R cryst value of 18.29% and 18.14%, respectively. Both models have r.m.s. deviations in bond length of 0.005 Å and in bond angles of 1.28. Diagrams were computed using MOLSCRIPT 25 , RASTER3D 29 ( Figs 2a and 3a, b) , POVRAY ( Fig. 1a ; see http:// www.povray.org) and GRASP 30 (Fig. 1b) .
